Text Size

Minimum Dose CT Post Lung Biopsy

This study has been completed.
Sponsor:
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00188162
First received: September 12, 2005
Last updated: April 20, 2007
Last verified: September 2005
History of Changes
  Purpose

The aim is to evaluate whether Minimum Dose CT (MnDCT) is useful in the management of patients post Lung Biopsy


Condition Intervention Phase
Lung Cancer
 Device: CT
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Can Minimum Dose CT Post Lung Biopsy Predict Patient Outcome?

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • Detection of Pneumothorax

Estimated Enrollment: 100
Study Start Date: January 2004
Study Completion Date: September 2005
Detailed Description:

Patients post Lung Biopsy have a chest X-ray (CXR) and a MnDCT post lung biopsy. Both studies are compared for the detection of a pneumothorax

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All Patients having a lung biopsy

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188162

Locations
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Narinder Paul, FRCP C University Health Network, Toronto
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00188162     History of Changes
Other Study ID Numbers: 03-0898
Study First Received: September 12, 2005
Last Updated: April 20, 2007
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 21, 2013